Macter International Limited received official approval to manufacture pre-filled syringes and pre-filled pens at its biotech facility, marking a major step forward for the pharmaceutical company.
The company informed the Pakistan Stock Exchange on Thursday about securing the necessary licenses for both types of manufacturing.
The approval puts Macter in an exclusive position. The company can now produce all three types of injectable biotech medicines—vials, pre-filled syringes, and pre-filled pens.
This matters for patients. Pre-filled syringes and pens are easier to use than traditional vials, which require drawing medicine into a syringe manually. The new formats reduce errors and make self-injection simpler for people managing chronic conditions like diabetes.
Macter says the new licenses will help it launch advanced biotech products that offer better treatment results and greater convenience for patients.
Founded in 1992 as a private company, Macter went public in 2011. The firm makes and sells pharmaceutical products across Pakistan.
The licensing approval positions Macter to compete in the growing market for user-friendly injectable medications, an area where patient demand continues rising as more people need regular injections at home.
